Monitoring Parameters for Colon Cancer Patients on Second Cycle of FOLFOX Chemotherapy

Introduction to Monitoring

• For a patient with colon cancer receiving their second cycle of FOLFOX chemotherapy, monitoring of complete blood counts, liver function tests, renal function, electrolytes, and assessment for peripheral neuropathy is necessary before each cycle, as recommended by the European Society for Medical Oncology, based on evidence from Annals of Oncology 1

Clinical Assessment and Renal Function

• Assess renal function before each cycle as part of standard monitoring, which is important for dose adjustments and managing electrolyte abnormalities, according to the European Society for Medical Oncology, based on evidence from Annals of Oncology 1
• Perform a focused physical examination to assess performance status and ability to tolerate treatment, as suggested by the National Comprehensive Cancer Network 2

Tumor Response Evaluation

• Response evaluation should occur after 2-3 months of treatment using CT scan with contrast, and monitor CEA levels if initially elevated, as recommended by the European Society for Medical Oncology, based on evidence from Annals of Oncology 1 and other guidelines 3

Treatment Modifications

• Consider discontinuing oxaliplatin after 3-4 months if significant neurotoxicity develops (≥grade 2) while maintaining fluoropyrimidine, as suggested by the National Comprehensive Cancer Network 4, 5